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Executive Summary
The Opportunity
The pathology industry has an impact on seventy percenti of medical decisions made,
yet this industry is burdened by errors and inefficiencies. Mistakes in surgical pathology
laboratories cost labs and insurance companies approximately $2.1 billion every year in the
United States aloneii. Mislabeling of tissue samples and contamination of specimens, which are
common sources of pathology lab errors, result in improper diagnoses, leading to unreported
cancers and unnecessary surgeries and painful treatments. Lawsuits resulting in awards of up to
$3 millioniii have been reported just from problems with tissue sample handling. Most important,
nearly seven million laboratory cases a year contain an error that could harm the patient.iv
In addition to patient harm due to misdiagnoses, manual handling of tissue samples can
produce personnel stress on pathology laboratories. The number of pathologists’ assistants (PAs)
is expected to decline and demand for them to growv in the next two decades as a consequence of
our aging population. The decreased supply of PAs and increased demands on them are likely to
lead to a higher tissue handling error rate in the future.vi Automation is a way to address both
issues: it decreases human errors due to manual handling of tissue samples and also allows
pathology labs to handle more samples with fewer employees.
The mission of BioBotic Solutions is to eliminate inefficiencies and errors in pathology
laboratories. As a first step, we are introducing the PathOne and our patent-pending BioBox,
which together will automate the manual transfer of biopsy tissue specimens in pathology
laboratories. The $300 millionvii annual market for the consumable specimen transport
containers and biopsy bags that the BioBox will be replacing is growing at approximately 5%
CAGR per year.viii
Product and Competitive Advantage
Our solution consists of two components that work together: the PathOne machine and
the consumable BioBox. To minimize capital requirements, we are following the “Xerox
model:” we are partnering with a manufacturer to develop, manufacture, distribute, and service
the PathOne, while we focus our efforts on our patent-pending BioBox. The PathOne consists of
(1) a robotic arm that transfers tissue samples from the BioBox to a cassette (a small container),
(2) an automatic bar code labeler, and (3) a conveyor belt that moves the tissue from initial
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reception in the lab to a container where it awaits transfer to the diagnostic area of the lab.
The PathOne will greatly reduce the time needed to perform the current labor-intensive and
error-prone tissue labeling and transfer process.
The BioBox replaces the separate containers and biopsy bags that are currently used to
handle tissue samples with a single container that includes both.

Figure 1: BioBox

By combining these two separate components into one (see Figure 1), the
tissue sample never leaves the biopsy bag once a surgeon has placed it in the
BioBox in the operating room. This reduces the risk of cross-contamination of
tissue samples, which accounts for about two-thirds of specimen errorsix.
The BioBox was invented by a pathologist at the University of Arkansas for
Medical Sciences (UAMS) who saw the inefficiencies in the current method
for tissue sampling employed in pathology labs. A prototype has been
developed at the University of Arkansas by a team of biomedical engineers led
by our CTO.
Management Team
Our management team is diverse and has expertise in pathology, entrepreneurship,
finance, chemistry, and engineering. Our Interim Chief Executive Officer and Chief Financial
Officer, Michael Iseman, is an honors Finance major at the University of Arkansas (UA). Rachel
Zweig, our Chief Operating Officer, is a Mathematics and Chemistry major at Hendrix College.
Our Chief Technology Officer, Kelley Coakley, is a Biomedical Engineering major at UA and
led the development of the prototype for the BioBox. Maria Driesel, our Chief Business
Development Officer is a Master’s candidate in Engineering Management and was a scholar of
the Manage&More Qualification Program for Entrepreneurs in Munich, Germany.
Dr. Shree Sharma, a medical researcher and pathologist at the University of Arkansas for
Medical Science (UAMS) and the inventor of our technology, will serve as Chief Scientific
Officer. We are seeking a permanent CEO with extensive experience in the pathology industry
and a Director of Sales and Marketing.
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Offering, Financial Summary & Exit Strategy
We are currently seeking seed funding of $400,000 in the form of convertible debt to
finish developing and testing our prototype and to hire a permanent CEO. We will be seeking an
additional Series A funding round of $750,000 in 2015 to fund the cost of validating our initial
units and acquiring initial customers. Series B funding of $1 million will be sought in January
2016 to penetrate the market and provide operating capital for growth.
Table 1: Investment/Funding Rounds

Investment

Amount

Angel

$400,000

Series A

$750,000

Series B

$1,000,000

Structure
Convertible
Debt
Preferred
Equity
Preferred
Equity

Timing

Uses

May 2014

Business & Product Development

January 2015

Validation and Customer Development

January 2016

Production and Market Penetration

We have identified multiple international medical manufacturers as potential acquirers of
our technology. Becton Dickinson, Copan and Roche all provide automation solutions to the
pathology industry and have a history of acquiring growing companies similar to BioBotic
Solutions. Becton Dickinson’s earnings statements show an average of $250 million spent on
acquisitions over the past four years, and Roche recently acquired BioImagene, an innovative
leader in the field of digital pathology workflow and analysis, for $100 million in its 6th year of
operation. Based off of an 8x EBITDA plus cash multiple, which is significantly less than the
industry average of 20x earnings, and including discounted future earnings under contract,
BioBotic Solutions will be valued at $80 million at the start of 2019. This offers a return of 36x,
26.5x, and 8x to Angel, Series A, and Series B investors, respectively.
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Company Overview
History and Current Status
Pathologists handle the majority of the behind-the-scenes work in the medical field.
Although they have very little patient interaction, they play an important role in the tissue
examination that leads to 70% of all disease diagnosesx. BioBotic Solutions’ area of focus in the
pathology industry is that of specimen grossing. Grossing is the entirely manual process of
transferring a tissue sample from a container into a biopsy bag, which is then placed in a cassette
(small container) before being sent off for processing and diagnosis.
The pathology industry currently faces three major issues: inadequate quality control,
such as mislabeling of specimens and contamination, insufficient laboratory staffing, and
financial constraints. Seeing these problems in the lab, Dr. Shree Sharma invented a solution that
addresses each of them. Dr. Sharma is employed at UAMS, which filed a patent application for
the BioBox (U.S. patent application #20/120,220,044) in 2012. The filing attorney, Blake
Glasgow, of Wright, Lindsey & Jennings LLP, has been recognized by Mid-South Super
Lawyers in the field of intellectual property. To move his solution from an idea to the market,
Dr. Sharma reached out to the University of Arkansas for assistance in developing the prototype
and the business.
BioBotic Solutions was founded by undergraduate students at the University of Arkansas
and Hendrix College in the fall of 2013. We have made significant process in advancing the
technology after speaking with potential customers, the FDA, robotic manufacturers, medical
supply manufacturers, and industry experts. We hold an exclusive option on an exclusive license
for the technology from UAMS BioVentures. To develop the prototype, we partnered with a
team of UA biomedical engineering students, led by CTO Kelley Coakley. We are seeking seed
funding for the prototype development of our robotic system, the PathOne, and for hiring a
permanent CEO.
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Mission and Vision
Recognizing the need to decrease errors in the tissue handling process and save the
pathology industry both time and money, our mission is:
“to develop technologies that automate the pathology laboratory to increase efficiency and
decrease both costs and errors that lead to misdiagnoses.”

We envision that our tissue handling process will be the industry standard by 2021.

Goals, Objectives and Strategy
In order to realize our vision of becoming the industry
and achieving
our sales
Figure 2: standard
Goals, Objectives,
and Strategies
goals, we have developed a detailed
outline of our objectives and
milestones. Our core strategy is to
outsource production, distribution, and
servicing of the PathOne, while
focusing on sales of the BioBox. We
will maintain close contact with our
end users to meet their needs with our
customer-driven solutions. To minimize
capital outlays, we will follow a “Xerox
model.”
We will sell the PathOne and BioBox
via
reagent rental agreements with pathology
labs. With a reagent rental agreement,
Multi-Craft Contractors, or our chosen
manufacturer, will install the PathOne at no or low cost to the lab. Labs will then be charged a
premium for each BioBox purchased. The price of the BioBox will depend on a lab’s projected
volume. For a lab processing 40,000 samples a year, each BioBox will be priced at $5.00.
The pathology labs will also pay our manufacturer $10,000 per year for the service agreement,
which is typical in the industry. After talking with pathologists, we have concluded that this is
the most viable sales strategy, as labs will be more willing to purchase the equipment if it does
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not require a large upfront capital investment. The milestones associated with each round of
funding are outlined in Figure 2.

Product
Features and Current Stage of Development
Most pathology laboratories are privately owned and independent of hospitals.
Pathology laboratories send containers for biopsy samples to hospitals that have contracted for
their services. The containers are sent in bulk to the hospitals, and the surgeon, nurse or other
qualified personnel selects the appropriate container for the biopsy before surgery. After surgery,
the container with the sample is returned to the lab.
Our innovation consists of two products: (1) the PathOne, which is a robotic system
placed at the front end of laboratory to automate the manual specimen labeling and handling
system currently used in labs and (2) the BioBox, which will replace the container sent to the
hospital and the biopsy bag into which the tissue sample is manually placed in the lab.
Figure 3: Pathology Workflow

The differences between the manual grossing process and the automated PathOne
grossing process are outlined in Table 2.
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Table 2: Comparison of the Status Quo and the PathOne
Status Quo

PathOne

PA receives tissue in container

PA receives tissue in BioBox and places it on PathOne
conveyor belt

PA labels cassette

Barcode is scanned and printed on cassette

PA removes tissues from container

Robotic arm uncaps tube and removes bag

Verbal description of the specimen

HD camera photographs specimen in transparent bag

PA places specimen in biopsy bag

(Specimen already in biopsy bag)

PA places bag in cassette

Robotic arm places bag in cassette

PA disposes of container in clinical waste

PathOne discards BioBox in clinical waste

Following this process, the cassette is sent to the diagnostic laboratory, an area of
pathology that is already highly automated.
PathOne
The PathOne is an automated robotic system that is used at the front end of pathology
laboratories. The small, approximately three-foot system can fit on a current lab station table and
will not disrupt a lab’s workflow. It is made up of a conveyor belt, a robotic arm, a storage
container of different cassettes, a barcode scanner and printer, and a high definition camera.
The cassettes are containers in which specimens are placed for further processing and are already
used in the pathology industry; we will not be introducing new cassettes or replacing what is
currently used. The robotic arm will have six degrees of freedom, and a special hand piece to
handle the biopsy bag; this system may be the source for a future utility process patent
application. PAA Automation and Multi-Craft Contractors, both robotics manufacturers that
have given us insight on their manufacturing process, have assured us that our system can be
developed and manufactured with ease. The PathOne does not come in direct contact with tissue
samples and requires no FDA certification.
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Figure 4: PathOne

BioBox
Our patent-pending BioBox (see Figure 4) consists of a conical polypropylene test tube
that includes an inset, transparent biopsy bag that is held in position by prongs on the inside of
the test tube. The bag will be made of solvent resistant nylon (Industrial Netting: Catalog
number: NN 3100 Nylon Mesh) that fits into industry-standard cassettes. A liquid preservative,
10% neutral buffered formalin (Formaldehye 50-0-0), will be in the tube to ensure the specimen
is fresh upon delivery to the laboratory.
Figure 5: BioBox
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The BioBox is a Class II device as defined by the United States Food and Drug
Administration (FDA) and must meet the FDA’s Good Manufacturing Practices requirements.
The BioBox prototype was designed in AutoCAD and has been 3D printed at the University of
Arkansas. Our next steps are to send our prototype to a manufacturer and work with them to
produce the BioBox on a larger scale.

Benefits
We not only protect patients, but we also offer an affordable and timesaving solution to
pathology laboratories, taking them one more step towards the 100% quality control program
they have told us they want. In contrast to the current method of manual grossing, after the
doctor places the tissue sample in the biopsy bag, the sample never leaves the bag again,
meaning no chance of cross-contamination or specimen mix-up.
During transfer from the BioBox to a cassette, a picture is taken by the PathOne to verify
that the laboratory received the sample and to document the specimen; this will replace current
inconsistent verbal specimen descriptions. In addition, the PathOne can operate 24/7, relieving
the bottleneck that currently characterizes end-of-day operations. Pathologists at both NWA
Pathology and UAMS have reported this as one of the biggest problems currently facing them
and their laboratories.
By automating the grossing process, PAs, technicians, and residents are available to do
other important tasks within the laboratory that require analytical skills and cannot be automated.
Staffing difficulties have been widely reported by the American Society for Clinical Pathology,
and automation would eliminate the need for one or more of those positions, depending upon lab
volume, helping to alleviate the staffing issue.
We will also increase laboratories’ value proposition to their customers, the hospitals
whose samples they process. Laboratories using the PathOne will have lower operating costs and
can pass on their cost savings to hospitals and/or increase their profit. More important,
these laboratories can advertise lower error rates and increase their revenues as the number of
samples they process increases. Being able to differentiate themselves is especially important for
labs in metropolitan areas, such as New York City and Los Angeles, which have over twenty
pathology laboratories competing for business.
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Competitive Analysis
Our patent-pending BioBox, strategic alliance with UAMS, and relationships with
pathology laboratories give us a strong competitive advantage. UAMS has agreed to host our
pilot deployment of the PathOne to validate its functionality and reliability. Also, our inventor,
Dr. Sharma, is well respected and has a large network within the industry. We have also
developed a strong network as we have developed the business.
We contracted with a third party market research firm, Invention Evaluator, to gain a
further understanding of the industry and the feasibility of our solution. The report yielded
favorable results, identifying our patent application as very useful, novel, and inventive, giving it
a high probability of being granted and creating a strong barrier to entry for potential
competitors.
Furthermore, our position as an industry first mover is a competitive advantage. Being a
first mover will allow our company to validate our solution and establish credibility with
customers without the concern of any direct competitors. Due to the length of time required for
validation, we anticipate being able to sell to pathology laboratories before competing
technologies are ready for purchase. In addition, the length of the contract for reagent rental
agreements, typically three to five

Figure 5: Market Advantages

years, will allow us to evaluate
the PathOne, improve it based on
customer feedback, and deepen
our relationships with pathology
laboratories.
Finally, our system offers
a variety of advantages in
comparison to our indirect
competitors in the market, as seen
in Table 3 and Figure 5. Our
direct competition is the status
quo of manual handling, which
we have described above.
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A third-party research firm has done a patent search on our technology and verified that
there are no directly competing technologies on the market or in the pipeline today. Automation
technologies are available for other processes in the pathology laboratory, and the PathOne
would integrate with these to help streamline the laboratory workflow. Upon an issuance of a
patent for the BioBox, there will be even greater barriers to entry for other laboratory robotic
manufacturers.
An indirect form of competition is DNA matching analysis, which can be used to catch
specimen mix-ups after they occur, but this is costly, time consuming, and catches mistakes
rather than prevents them. KnowError is an example of a company providing this service;
after taking a swab sample of the patient’s cheek, they match it with the DNA of the biopsy if the
sample comes back positive. DNA matching analysis is seldom used, however, due to the high
cost-about $1500 per case-and labor needs and increased turnaround time.xi
Table 3: Product Advantages
Advantage

BioBotic

DNA Matching

Manual Handing

Staff Needed

0

≥2

2

Cost per Sample

$5

$200-$1500

$5

Lower Chance of Specimen Mix-up

!

!

Market and Competitive Analysis
Market Overview
The annual market for the consumable specimen containers and biopsy bags that the
BioBox will replace is worth about $300 million today, and the number of biopsies performed
each year is increasing at a CAGR of 5% xii. Revenue for anatomic pathology labs, which are
responsible for grossing biopsy specimens, grew 16% from 2006-2009.xiii These point to a
growing market for biopsies and the consumable products used in them.
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Driving Forces
With worldwide trends such as an aging population, increasing cancer rates, and a larger
focus on health care, pathology laboratories are processing more specimens than ever before.
Among Medicare enrollees, the number of biopsies performed increased at a compounded annual
growth rate of 3% between 1997 and 2008.xiv Technological advances are playing a large role in
the world’s leading industrial countries, and automation has replaced many manual processes,
such as in vitro diagnostic systems. We have identified three industry-specific forces that provide
an opportunity for BioBotic Solutions.
Quality Control: Mislabeling and Cross-Contamination
Human errors during the manual grossing process include the mislabeling of specimens,
cross-contamination, and spillage or losing small tissue samples during the transfer from the test
tube to the cassette. Washington University and the American Journal of Clinical Pathology have
conducted studies of errors committed during the routine pathology process. These studies
examined over 13,000 specimens and found error rates of 3% and 0.93%, respectively.
Assuming 0.93%, the low end estimate, a midsize lab processing 40,000 samples in a year will
make 370 preventable mistakes per year. The Institute of Medicine reported that 70% of
specimen-identification errors happened in the gross room.xv Errors that are caught can cause lab
staff to spend fifteen to forty-five minutes correcting the mistake. xvi, xvii Six percent of errors,
or nearly 4 million cases a year, lead to patient harm, which demonstrates a need for an error-free
solution.xviii
Human Resources: Lack of Laboratory Personnel
In its Wage and Vacancy Survey of Medical Laboratories, the American Society for
Clinical Pathology found that 43% of laboratories reported difficulties hiring personnel,
which they attributed to underqualified applicants, retirement, and high turnover.xix
Quest Diagnostics, which employs about 8,500 lab professionals, making it one of the nation's
largest lab companies, currently has about 1,200 job openings nationwide, illustrating their
staffing problem.xx
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When labs face a high volume of specimens to gross, they either use less qualified
personnel or improvise by pulling staff from other work areas and asking technicians to work
double shifts. Not only does this put a strain on the laboratory, but it also increases the risk for an
error by having under-trained and overworked employees in the gross room.
The PathOne will free up PAs to gross larger tissue samples and specimens that require
special orientation or manipulation before being tested. These tasks cannot be automated and
require the expertise of a trained PA. Sixty percent of the tissue samples that labs typically
receive, however, will be able to be grossed by our solution.
Financial Constraints: Decreased Reimbursements
Due to the expiration of the Technical Component (TC) Grandfather Clause and recent
healthcare reforms, federal reimbursements to labs for the Current Procedural Technology (CPT)
code for the grossing of small biopsy specimens decreased by 52%. From 1999 to 2012, the TC
Grandfather Clause provided reimbursement to pathology laboratories for much of the clinical
work done in the lab,xxi but that reimbursement rate has now ended. Pathology labs are not
getting compensated for this lost revenue elsewhere. As a result, they are desperate for costsaving measures, such as the PathOne and BioBox.

Market Acceptance
Due to these driving forces, pathology laboratories will have a strong need to adopt new
automation technologies. The pathology industry has a bias towards the status quo of manual
tissue handling. Pathologists with whom we have talked, however, recognize inefficiencies in
grossing and are excited about our technology. Pathologists drive the purchasing decisions in
most labs and are the decision makers in independent laboratories; once new technologies have
been validated and shown to be reliable and effective, they can make purchasing decisions in a
monthxxii. To encourage rapid adoption of our technology, we will be building the cost of the
PathOne into the consumable BioBox. This approach is very common in the industry and is
widely accepted by pathology labs.
The average salary of a pathologist’s assistant is $73,000, and that of a lab technician is
$42,000 to $49,000iv. Laboratories currently pay $3.35 for the containers and biopsy bags used to
process a specimen. The BioBox will replace these disposables, and will also remove the labor
cost associated with grossing each specimen. With our integration, labs will be able to eliminate
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or avoid hiring the equivalent of one to two full time positions. Even a lab on the conservative
end of our target market, one processing 40,000 samples per year, will experience an immediate
cost reduction due to personnel savings.

Management Team
Management Profile
Dr. Shree Sharma: Chief Scientific Officer
Dr. Shree Sharma has been working as an Assistant Professor in the Department of
Pathology at the UAMS since 2012. He finished his pathology residency from one of the premier
institutes in India (AIIMS, New Delhi) before moving to the United States in 2007.
He specializes in renal pathology and finished his fellowship from Columbia University Medical
Center in New York in 2012 Dr. Sharma is interested in integrating technology into the
day-to-day workings of the laboratory to improve patient care. He has more than 25 publications
in peer-reviewed journals and book chapters and has presented many abstracts and posters at
national and international conferences. . Leica recently telecasted his webinar on mobile
technology in pathology. Dr. Sharma is a member of many pathology organizations, including
the Innovation Educational Products Committee of the United States and Canadian Academy of
Pathology (the biggest pathology organization in U.S. and Canada). Dr. Sharma is a young,
energetic pathologist and sees opportunities to treat problems that have long gone unaddressed in
pathology labs; that passion led him to invent our technology.
Michael Iseman: Interim Chief Executive Officer and Chief Financial Officer
Michael Iseman is a senior at the University of Arkansas, where he studies Finance and
Spanish. He spent a semester studying business and Spanish in Spain and speaks Spanish
fluently. He served as an intern at the ARK Accelerator, a startup accelerator providing young
technology and retail startups the resources they need for success. At the ARK, he gained
exposure to the practical steps needed for cost-effective early business development.
He currently works as an associate at Elevate Performance, a consulting firm providing
leadership development resources to the CEOs of Northwest Arkansas businesses through CEO
Forums. There, Michael has established a powerful network with the more than forty regional
leaders in business, and gained exposure to the issues and opportunities facing a C-Suite
executive.
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Rachel Zweig: Chief Operating Officer
Rachel Zweig is a sophomore at Hendrix College and is pursuing a double major in
Chemistry and Mathematics. She is co-captain of the Hendrix women's soccer team and made
the Academic All-District Team in 2013. Rachel is an Arkansas Governor's Distinguished
Scholar and was a National Merit Finalist in 2012. She worked in her family’s small business for
many years and has pursued her own entrepreneurial endeavors since she was 10.
Kelley Coakley: Chief Technology Officer
Kelley Coakley is a senior at the University of Arkansas studying Biomedical
Engineering and Mathematics, with a Sustainability Minor. She is on the premedical track and
has been accepted into UAMS, where she will start medical school in the fall of 2014.
Kelley has been participating in research at the UA for three years and leads the team of
biomedical engineers developing the BioBox.
Maria Driesel: Chief Business Development Officer
Maria Driesel was born and grew up in Germany. She is studying Engineering
Management at the Technical University of Munich with a focus in Innovation, Entrepreneurship
and Project Management. As a fellow of the 18-month Manage&More Qualification Program
she gained extensive knowledge in entrepreneurship. Manage&More focuses on working in
interdisciplinary teams as well as developing and implementing business concepts to create
innovative and marketable products and services. As a participant of this program, Maria applied
her education to innovation projects with BMW Group and Bosch. In addition, she gained a lot
of experience in project management with her work at IMP Management GmbH, where she
worked in the field of office space planning.

Future Needs and Compensation
The first key hire for BioBotic Solutions is a CEO with extensive experience in both the
pathology industry and lab automation equipment industry. In 2015, we anticipate hiring a
Director of Sales and Marketing to lead customer development as the PathOne finishes
validation and becomes market-ready. The Director of Sales and Marketing will lead the
management team in securing our first five accounts in 2016.
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The current management team will be compensated with an annual salary of $25,000,
growing at 7% beginning in 2015. Once the permanent CEO has been hired, he or she will start
with an annual salary of $150,000. Both the management team and the CEO will be compensated
with equity distributions based on longevity and the achievement of both personal goals and
company milestones. Provided that all goals are met, equity will be distributed to the CEO at a
rate of 2% semiannually and to the management team at a rate of 0.5% semiannually.
This agreement will expire and management benefits will be reevaluated after three years, in
2017, with a maximum of 24% ownership distributed as compensation.

Board of Advisors
Table 4: Board of Advisors
Advisor/ Position/
Company

Focus

Qualifications

Thomas Blodgett
Director of Operations
Multi-Craft Contractors
Inc.

Automation and
Robotics

• Developed A&R program at Multi-Craft Contractors
• Served as the director of project development

Medical Device
Sales

• 10+ years’ experience in medical sales
• Co-founder and CEO of Tears for Life, a medical start-up
• Medical sales channel knowledge and experience

Pathology
Laboratories

• 11+ years’ experience in the pathology industry
• 4 years’ experience on hospital committees
• Purchases medical equipment for NWA Pathology

Jared Greer
Medical Device Sales
Rep.
Medtronic
Lucas K. Campbell, M.D.
Partner and President
Northwest Arkansas
Pathology
Paul Mlakar
Senior Executive
Blackstone Construction,
LLC

Medical Start-ups

•
•
•
•

13+ years’ experience in start-up, strategy, and improvement
Raised $3.3 million in start-up funding for medical start-up
Founded 4 companies
Operations Manager of construction start-up; increased sales
from $6m to $50m in 4 years
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Operating Strategies
Validation
In order to validate our technology, we will run six-month trials at three beta sites of
various sizes: laboratories with high, medium, and low volume of biopsy specimens. We will
first run dummy samples and then progress to discarded tissue samples before running tissue
samples intended for diagnosis. After manufacturing, no additional cost will be incurred to run a
beta site in the UAMS pathology laboratory due to their vested interest in the success of the
venture. For the other sites, we will negotiate with the laboratories to find a suitable payment
arrangement. Two possibilities are giving the laboratory equity in BioBotic Solutions and giving
the laboratory a discounted rate on the BioBox for one to two years.

Production
After validation is complete, we will outsource manufacturing, distribution, and servicing
of the PathOne system to minimize capital requirements. Multi-Craft Contractors has expressed
interest in manufacturing the PathOne and has the capabilities to distribute and provide
aftermarket service for the PathOne. We will provide our customers with a warranty, technical
support, maintenance, inspections and upgrades for our system through BioBotic Support,
which Multi-Craft will operate and manage. This service arrangement is typical within the
industry.
To produce the BioBox, we will contract with a manufacturer, such as Fisherbrand,
that has established distribution channels within the pathology industry. We will negotiate a
supply agreement with the manufacturer.

Sales and Marketing Strategy
Our initial sales and marketing strategy is to target laboratories with a high volume of
specimen samples (more than 40,000 biopsy samples annually) and those that are in regions with
an acute labor shortage, such as the Western U.S. We also plan to focus on high-end laboratories
that can become leaders and best-practice examples for new technology.
We will initially focus on the U.S. market, which accounts for the largest market share of
lab automation equipment and consumables. Our next step will be an expansion into Canada,
which has the same certification requirements as the United States. After gaining traction in
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North America, we will open operations in the European and Australian markets, where
laboratory automation is appealing due to stringent laboratory accreditation requirements.
After talking with pathologists and purchasing decision-makers in pathology labs,
we have identified three key way to market our technology. First, we will raise product
awareness at pathology conferences and trade shows and visit labs, where we will demonstrate
our technology and expand our network within the industry. Second, we will conduct efficacy
studies during the validation of the PathOne and publish the results in pathology trade journals,
such as Modern Pathology, Critical Values and AJCP. Pathologists have told us this is critical in
order to gain market acceptance. Finally, pathologists have told us that after our technology has
been verified, it will spread by word-of-mouth. After our initial market penetration our
management team will continue advertising, giving lab demonstrations, and exhibiting at trade
shows.
In 2015 we will hire a Director of Sales and Marketing to lead our customer development
process and increase market awareness as the PathOne finishes validation. The management
team and director of sales and marketing will act as our sales force in 2016, when we project
selling to our first five accounts. After this initial market acceptance, we plan to contract with a
medical distributor to represent our product to labs. Medical distributors will have proven sales
channels and preexisting relationships with the laboratories.

Research and Development
Our R&D team will seek to improve on our existing technology to make the grossing
process more efficient. We will work on new solutions to improve the workflow in the pathology
lab, such as a way to automate the decalcification process for bone marrow. We anticipate
applying for both domestic and international patents for new intellectual property created in our
labs, and have included patenting expenses under research and development in our financial
projections.
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Risk Management
As with any new company, risks must be anticipated and mitigation plans adopted.
We have identified several risks that we may encounter and developed mitigation plans for each
of them.
Table 5: Risk Management

Risk

Explanation

Threat Level

Impact Level

Market Adoption

Slow adoption

High

Moderate

Validation

System not validated

Low

High

Warranty

System requires frequent servicing

Low

High

Patent issuance

Patent still pending

Moderate

High

Competition

Established competitors

Moderate

Low

Political

Health care policy change

Low

Low

Financial

Yet to raise capital

Moderate

High

Management Team

Need to hire qualified management team

Moderate

High

Product

Additional development and validation of

Low

High

PathOne and BioBox needed

Market Adoption
Pathology is typically the last sector of the healthcare industry to adopt change.
Initial conversations with pathologists, however, have demonstrated that once we can show
PathOne is reliable and efficient, pathologists are interested in bringing PathOne into their labs.
In addition, the number of pathologists is forecasted to decrease significantly after 2014,
resulting in an increased need for automation in the lab. Labor restrictions and stringent
accreditation requirements in Europe make it likely that European laboratories will readily adopt
our systemxxiii.
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Validation
We will test the PathOne at three beta sites with varying sample volumes for six to twelve
months and make necessary changes to optimize the reliability and effectiveness of the PathOne.
We will use these beta sites to conduct exhaustive studies and collect data on the effectiveness
and integrity of PathOne and publish these in trade journals. We will also work closely with
these labs to make incremental improvements, ensuring a one year validation.
Warranty
To decrease the need for extensive servicing of our system, we will perform multiple
pre-market tests to ensure that our system will stand up to the rigors of pathology laboratories,
which often process hundreds of samples a day. In addition, validation will require that our
system is durable. We will continue to run testing sites so we can continuously make and
monitor changes to the PathOne. This will ensure that service fee paid to BioBotic support will
cover costs associated with servicing and provide our manufacturer with profit.
Patent
We anticipate being awarded a patent for the BioBox. Invention Evaluator,
an independent firm, examined the patent and gave it a favorable outlook. If the patent is not
issued, we will establish and build upon our reputation as a low error system and be ahead of the
market as a first mover. Later, to protect against patent expiration, we will invest in R&D to
expand our patent and file for a utility patent by making continual improvements to our system,
including how to expand the tasks covered by the system. In addition, we will build brand equity.
Competition
There are currently no direct competitors to PathOne, and Google searches have not
turned up any competing technologies in the pipeline, as verified by Invention Evaluator.
However, we realize that other companies like us might be trying to take advantage of this
opportunity. We will initially target areas with a high need for automation and then build upon
established relationships and brand equity to move into other areas. We will use our service team
and our established reputation as a low error system as key selling points.
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Political
The Affordable Care Act has resulted in a fifty-two percent decrease in reimbursement to
pathology laboratories for the grossing of small biopsy specimens. The decreased funding makes
our system more attractive. Another policy change could result in a higher reimbursement rate,
but given the lack of political appetite to make more health care policy changes and the desire to
cut government costs, this risk is low.
Financial
We are still seeking capital and will not be able to move forward with the product before
finishing the development of our prototype. The funding we are currently seeking will be
primarily used for prototype development.
Management
BioBotic Solutions is currently run by pathologist Dr. Sharma and a student management
team; we fully anticipate bringing on an experienced executive and other managers as we
validate our products. We will hire an experienced CEO in the medical and health care industry
to provide leadership to the company and a Director of Sales and Marketing.
Product
PAA Automation and Multi-Craft Contractors, two potential manufacturers of the
PathOne, have assured us that the PathOne can be manufactured easily, and Multi-Craft has
agreed to do R&D on the PathOne and make necessary modifications to address the needs of
both pathology laboratories and manufacturing. The BioBox has been developed by a team of
biomedical engineers at the UA, and they have identified the necessary material for the inset
biopsy bag and the tube. We will work closely with the manufacturers of both the BioBox and
the PathOne to ensure feasibility and make alterations as needed. We will communicate any
changes in the manufacturing of the BioBox or the PathOne that may affect the design of the
other product with the appropriate manufacturer to ensure compatibility.

21 | P a g e

Sources and Uses of Funds
BioBotic Solutions is seeking a seed funding round of $400,000 from angel investors by
May 2014 to finish prototype development and to hire a permanent CEO with experience in the
medical device and pathology fields. UAMS will be a free beta site, and we will look to contract
with two other labs of varying sizes to ensure rigorous product validation. By January 2015,
we will seek a Series A round of $750,000 to fund customer development and sales and
manufacture our initial units.
Table	
  6:	
  Source	
  and	
  Uses	
  of	
  Funds	
  

Sources and Uses of Funds
Seed Funding

Amount
$400,000

Patent Expenses

$20,000

PathOne Research & Design

$100,000

PathOne Development

$100,000

BioBox Development & Production

$14,000

Salaries and Wages

127,125

Other Employee Costs

$37,125

Series A Round

$750,000

PathOne Research and Development

$180,000

BioBox Production

$75,000

Installation & Integration

$30,000

Salaries & Wages with taxes

$210,750

Marketing and Customer Development

$12,000

Series B Round

$1,000,000

Round will be utilized to manufacture initial units and fund selling, general,
& administrative expenses in 2016. Investment will be supplemented by
income from initial sales to finance operating expenses.

22 | P a g e

Table 7: Investment/Funding Rounds

Investment

Amount

Structure

Timing

Uses

Angel

$400,000

Convertible
Debt

May 2014

Business & Product Development

Series A

$750,000

Preferred
Equity

January 2015

Validation and Customer
Development

Series B

$1,000,000

Preferred
Equity

January 2016

Inventory and Market Penetration

Offering and Exit Strategy
BioBotic Solutions is currently seeking angel funding for our seed round of $400,000 to
be structured as a convertible note. Interest on the note will compound annually at 8%, and the
note will convert to preferred equity upon the event of a Series A round, predicted to be in
January 2015. The note will convert at a 25% discount to compensate investors for the additional
risk taken on by investing in an early stage venture, and the conversion will cap at a $4 million
valuation. We will pursue Series B funding in January 2016. These funding rounds will be
allocated to product validation and customer development and will be structured as preferred
equity.
The state of Arkansas offers attractive incentives for investors in new, knowledge-based
companies such as BioBotic Solutions. We will apply for approval for Equity Investment Tax
Credits for Series A and B Investors. These credits give investors a 33% credit of the amount of
their investment on their Arkansas state income taxes. For non-Arkansas investors, these credits
can be sold. We will also seek state funding from the Risk Capital Matching Fund and in the
form of R&D tax credits. We have not included funds from these sources in our financial
statements, but they will reduce our investors’ risk and lower capital requirements should we be
approved for them.
After discounting projected revenues and comparing BioBotic Solutions to similar prerevenue firms, we predict a pre-money valuation of $3 million for Series A and of $10 million
for Series B funding rounds. Dr. Sharma, the inventor, will begin with 10% equity,
and incremental distributions will be made to the management team based on performance and
tenure, as outlined in management compensation. The equity of BioBotic Solutions will be
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divided into 100,000 shares, and Table 4 summarizes our anticipated equity breakdown after all
rounds of funding in January 2017.
Table 8: Projected Equity Distribution January, 2017

Party

Contribution

Percent Equity

UAMS

Patent

5%

Dr. Shree Sharma

Invention

10%

Management Team (combined)

Labor

12%

CEO

Labor

12%

Seed Investors

$400,000

18.6%

Series A

$750,000

25%

Series B

$1,000,000

10%

BioBotic Solutions

Retained

7.4%

Our primary exit strategy will be an acquisition by a large lab equipment manufacturing
company after we have gained sales traction. It is common in this industry for smaller companies
to be acquired after the market has accepted the technology. Some recent acquisitions of small
lab equipment companies by large lab equipment manufacturing companies can be seen in Table
4. An alternative exit strategy would be to exit pre-revenue after Series A, but prior to Series B,
at a projected valuation of $3 million, after the validation of our initial units. Becton Dickinson
has indicated an interest in pursuing technologies in the validation stage and taking them to
market. Although the returns for an earlier exit would be lower, a pre-revenue exit would give
our investors a quicker return on their investment and reduce their risk.
Table 9: Recent Lab Equipment Company Acquisition

Company

Acquired

Price

Becton Dickinson

HandyLab

$275m

Roche

Constitution Medical, Inc.

$220m

Roche

Biolmagene

$100m
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Assuming a discounted industry average P/E ratio of 8, we assume a valuation of 8x
earnings in 2018 plus 2x future earnings under contract. Future earnings under contract are a
result of the reagent rental agreement 5-year contracts. Revenue under contract was discounted at
20% to reflect the time value of money and an allowance for doubtful accounts and we assume,
using a discounted industry average, that 15% of revenues will be retained as earnings.
With these assumptions, and those outlined in the Notes to Financials, BioBotic Solutions will be
valued at $80 million at the start of 2019. An acquisition at this point would yield a 36x return
for Seed Funding Investors, 26.5x return for Series A investors, and an 8x return for Series B
investors.
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Appendix I: Pro-Forma Financial Statements
Notes to Financials
1. Revenue numbers include sales of 40,000 BioBoxes per year to each of our customers at
an average price of $5.00. Sales begin in 2016 with 5 laboratories. After partnering with
a national sales force, sales will grow to 50 laboratories in 2017, and increase to 200
laboratories in year 2018.
2. FDA certification for a Class II device will fall under the 510(k) guidelines, and will be
$4,328. The cost is incorporated into Research and Development in 2014.
3. UAMS will not receive royalties for sales of BioBox in the first three years of sale so that
growth is not stifled. Instead they will retain 5% equity in BioBotic Solutions to
compensate for patent usage.
4. Research and Development in 2014 increases in months when payments are made to our
manufacturing partner for PathOne development. . R&D expense in 2015 accounts for
production and delivery of three PathOne units to be tested at validation sites.
5. Based off of industry comparables, we assume manufacturing and distribution costs for
the BioBox will be $2.18.
Cost will decrease to $1.90 per Box as operations scale in 2017.
6. Amortization calculated straight-line over the 20-year life of the patent.
7. Accounts Payable assumes that 75% of payments are made in the current month, and
25% in the following month.
8. Accounts Receivable assumes that 60% of payments are received in the current month,
25% in the second month, and 15% in the third month. Billing will be on a contractual
level, and doubtful accounts are considered to be irrelevant.
9. CEO will start with a salary of $150,000 and Management team at $25,000. As outlined
in management compensation, these salaries are discounted and substituted with equity
options. Director of Sales and Marketing will start at $150,000. All salaries are expected
to increase at 7% annually. Salaries and wages do not increase at the scale of sales due to
our sub-contracting of the sales force. Payroll Taxes are calculated as 7.65% of salary and
wages. Benefits are calculated as 20% of salaries.
10. Office Equipment accounts for computers, phones and other general capital purchases
associated with operations and bringing on new employees, and will depreciate over a 4
year useful life.
11. PathOne units for use in lab demonstrations and trade show expositions are held as fixed
assets and are depreciated straight line over a 5-year useful life.
12. We estimate sales expenses of $100,000 in 2016 to compensate for travel and other
customer acquisition costs. After 2016, we will partner with a large medical distributor
with preexisting sales channels. We have allocated an additional 20% of total revenues to
selling costs after partnering with a distributor which is represented in COGS. Additional
costs are assumed to be in SG&A which is 10% of total revenues.
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13. Annual payments to Multi-Craft, or selected PathOne manufacturer, are $20,000 per
PathOne and accounted for in COGS. Service agreement fees are paid by the laboratory
directly to the manufacturer, and will not affect our financial statements.
14. R&D expenses are calculated on industry average of 8.8%, plus 10% for the years
2016-2018.
15. Inventory is not carried by BioBotic Solutions. MultiCraft Contractors will hold the
inventory for the PathOne, and we will pursue a supply agreement with manufacturer of
BioBox.
16. Distributions of 33% of profits will be remitted to investors in April on years after profits
are made so that members can make tax payments for the previous year.
17. Due to the nature of the reagent renal agreements, each contract with a laboratory will
initiate a 5-year revenue stream, or $200,000/year, for the BioBoxes. The portion to be
collected within the coming fiscal year moves to accounts receivable. These contracts
will represent $192,000,000 in future revenues at the end of 2018. Because the funds
have not yet been received, and the service has not yet been performed, this is an off
balance sheet account, and accounted for in the balance sheet footnote.
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Income Statement
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Statement of Cash Flow
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Balance Sheet

Off balance sheet account of future revenues under contract are $4 million in 2016, $43 million
in 2017, and $192 million in 2018.
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Appendix II: A Perfect Pattern Match
“Pattern Match.” It’s more than just a buzz word. Through the art of pattern matching,
and a lot of hard work, BioBotic Solutions was able to represent the University of Arkansas in
achieving unprecedented success in undergraduate business plan competitions. This truly is an
art, as it challenges the entrepreneur with a new, creative idea, to communicate it in terms that
their audience, whether a customer or investor, is comfortable with and can understand. For one,
people don’t always respond well to change, and most important, if it has worked well before it
will likely work well again.
The first step in effective pattern matching is to really understand your customer, and
uncover all relevant industry information. It is important to know how disruptive your new
technology is within the industry, and likewise, what are the most effective ways to incorporate
your solution into the industry to optimize rather than disrupt the current work flow? Most
importantly, what will make your customers most comfortable with purchasing your product?
After identifying the best practices within the industry, the entrepreneur is charged with the task
of communicating this to investors, who often are not familiar with the industry. We must
communicate this new idea with investors in terms that they understand so they are able to
clearly see the viability and investability of the business. If the idea is sound and communicated
effectively, the probability of a successful venture begins to increase exponentially.
One area in particular that we learned all aspects of the perfect pattern match was with
our ever-evolving business model. We eventually concluded on using “reagent rental
agreements” as our most effective strategy, which is essentially the “razor and blades” method
(see what I did there? – that was a pattern match). Initially we structured our business model
around a markup on the robotic equipment, and assumed the containers would be sold for
pennies on the dollar. After pitching to investors who were confused as to where and how we
would be making money, and receiving push-back from pathology laboratories, the business
model was revisited. We found that pathology laboratories are hesitant to make large capital
purchases due to their budgetary constraints and rapid advancements in technology within the
industry. They are more comfortable spreading the cost over a number of years into their
operating cash flows, and aren’t as concerned about owning the equipment. We were then tasked
with incorporating this new information into our strategy, and communicating it with all parties.
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We researched the reagent rental agreements, and they began to make sense. We would
place the equipment in the laboratory at no cost to the lab. Then we determine how many of our
containers that they would purchase per year, and set the price of the containers at a level that we
can recover the cost of the robotic equipment, manufacturing and delivery of the containers, and
retain a sufficient level of profits. This allowed us to better identify our initial target market,
communicate to them where and how much money they will save, and we had structured our
pricing strategy in a manner that they were most comfortable with. This was a win – win solution
for both our company and our customers, now we needed to communicate it with the investors.
This business model was somewhat complex, as we now had many players involved.
Manufacturers for both the container and the robotic equipment and the container, a potential
leasing partner, the laboratory and in some cases more were involved. Although the pathology
laboratories were familiar with this model, most of our audience had never heard of a “reagent
rental agreement,” and we struggled to communicate what we thought was a fantastic idea. We
eventually realized, with the help of our brilliant advisors, that although the vocabulary might be
new, the idea has been around since Xerox made huge profits by discounting printer sales and
charging a markup for copies in the 90’s. Once we began to communicate this idea as “the Xerox
method” or “the razor and blades method” we never had to worry about it as a friction point with
investors or critics.
The first step is having an idea, and it is crucial to do sufficient customer development,
problem interviews and market research. Once that has been achieved it will be easier to tell
whether or not your idea really solves a problem (if you can’t tell, then do more research). After
establishing that you have a viable venture, communication is the most important step in
progressing forward. We have found that the most effective way of communication is to meet
people where they are, and speak in terms and ideas that they will understand. That is the art of
the pattern match.
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Appendix III: Contact Information
Dr. Shree Sharma
+1 (502) 052 6363
sgsharma@uams.edu
Michael Iseman
+1 (816) 728 9331
miseman@email.uark.edu
Rachel Zweig
+1 (479) 422 7518
rezweig@gmail.com
Kelley Coakley
+1 (501) 844 7374
kcoakley@email.uark.edu
Maria Driesel
+1 (281) 908 2374
+49 173 91 07 498
maria.driesel@manageandmore.de
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